| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2215/CJN.11511114 |
| P8608 | Fatcat ID | release_lbpzxmrspfc2npqqdxc65k7zm4 |
| P932 | PMC publication ID | 4455219 |
| P698 | PubMed publication ID | 25887073 |
| P2093 | author name string | Ron T Gansevoort | |
| Hiddo J Lambers Heerspink | |||
| P2860 | cites work | Cubilin is an albumin binding protein important for renal tubular albumin reabsorption | Q24618773 |
| Cardiorenal end points in a trial of aliskiren for type 2 diabetes | Q28278569 | ||
| Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group | Q33157410 | ||
| Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides | Q33394150 | ||
| Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. | Q33762978 | ||
| Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis | Q33805412 | ||
| Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule | Q34183565 | ||
| Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction | Q34415281 | ||
| Cubilin is essential for albumin reabsorption in the renal proximal tubule | Q34457022 | ||
| Combining GFR and albuminuria to classify CKD improves prediction of ESRD. | Q34606387 | ||
| Screening for albuminuria identifies individuals at increased renal risk | Q34658059 | ||
| Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial | Q34787799 | ||
| Hermann Senator and albuminuria--forgotten pioneering work in the 19th century | Q34900896 | ||
| Changes in albuminuria predict mortality and morbidity in patients with vascular disease | Q35108899 | ||
| Sodium intake, ACE inhibition, and progression to ESRD. | Q35720736 | ||
| Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes | Q35721420 | ||
| Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis | Q35903126 | ||
| Renal tubule albumin transport | Q36041079 | ||
| Histological predictors for renal prognosis in diabetic nephropathy in diabetes mellitus type 2 patients with overt proteinuria | Q84967054 | ||
| Renal albumin absorption in physiology and pathology | Q36412414 | ||
| How does proteinuria cause progressive renal damage? | Q36621209 | ||
| Role of remission clinics in the longitudinal treatment of CKD. | Q36677647 | ||
| Albumin transport and processing by the proximal tubule: physiology and pathophysiology. | Q36848126 | ||
| The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogat | Q36966415 | ||
| Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts | Q37648704 | ||
| Microalbuminuria: target for renoprotective therapy PRO. | Q38206640 | ||
| Progression of renal injury toward interstitial inflammation and glomerular sclerosis is dependent on abnormal protein filtration | Q38236400 | ||
| Microalbuminuria: a parameter that has changed diabetes care | Q38281767 | ||
| Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies | Q38494065 | ||
| A prospective study of multiple protein biomarkers to predict progression in diabetic chronic kidney disease | Q39149761 | ||
| The role played by endocytosis in albumin-induced secretion of TGF-beta1 by proximal tubular epithelial cells | Q40184915 | ||
| Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. | Q40509707 | ||
| Protein overload-induced NF-kappaB activation in proximal tubular cells requires H(2)O(2) through a PKC-dependent pathway. | Q40737240 | ||
| Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins | Q41267402 | ||
| Proteinuria and tubulointerstitial injury | Q41610465 | ||
| Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. | Q43725750 | ||
| Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? | Q43905227 | ||
| Albumin induces NF-kappaB expression in human proximal tubule-derived cells (IHKE-1). | Q44151697 | ||
| Endothelin-1 in the kidney and urine of patients with glomerular disease and proteinuria. | Q44211866 | ||
| Transforming growth factor-beta(1) in the kidney and urine of patients with glomerular disease and proteinuria | Q44231172 | ||
| A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. | Q44319128 | ||
| Retarding progression of chronic renal disease: the neglected issue of residual proteinuria | Q44445107 | ||
| Effects of pathophysiological concentrations of albumin on NHE3 activity and cell proliferation in primary cultures of human proximal tubule cells | Q44473613 | ||
| Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy | Q45247211 | ||
| Combined angiotensin inhibition for the treatment of diabetic nephropathy | Q46129784 | ||
| The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension | Q46169157 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Albumin stimulates the accumulation of extracellular matrix in renal tubular epithelial cells | Q47343304 | ||
| Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. | Q48026114 | ||
| Renal phenotypic investigations of megalin-deficient patients: novel insights into tubular proteinuria and albumin filtration. | Q50358215 | ||
| Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells. | Q51088652 | ||
| The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease | Q56867091 | ||
| Intensive glucose control improves kidney outcomes in patients with type 2 diabetes | Q57312402 | ||
| Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure | Q67994101 | ||
| Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group | Q71979461 | ||
| ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group | Q73110915 | ||
| Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein | Q73799630 | ||
| Activation of mitogenic pathways by albumin in kidney proximal tubule epithelial cells: implications for the pathophysiology of proteinuric states | Q77998410 | ||
| Normoalbuminuric renal-insufficient diabetic patients: a lower-risk group | Q80280826 | ||
| Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency | Q80313261 | ||
| Sodium intake modifies the negative prognostic value of renal damage prior to treatment with ACE inhibitors on proteinuria induced by adriamycin | Q81624061 | ||
| High Level of Proteinuria During Treatment With Renin—Angiotensin Inhibitors Is a Strong Predictor of Renal Outcome in Nondiabetic Kidney Disease | Q82068501 | ||
| ONTARGET still OFF-TARGET? | Q83491265 | ||
| Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers | Q83716874 | ||
| Strengths and weaknesses of renal markers as risk factors and surrogate markers | Q84228067 | ||
| Surrogates under scrutiny: fallible correlations, fatal consequences | Q84770750 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 1079-1088 | |
| P577 | publication date | 2015-04-17 | |
| P1433 | published in | Clinical Journal of the American Society of Nephrology | Q15757929 |
| P1476 | title | Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View | |
| P478 | volume | 10 |
| Q40503443 | Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study |
| Q40436912 | Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality |
| Q91597492 | Albuminuria: a target for clinical trials in kidney disease? |
| Q91009115 | Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies |
| Q40046689 | Changes in Albuminuria and Subsequent Risk of Incident Kidney Disease |
| Q42722922 | Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease |
| Q38781550 | Developing Treatments for Chronic Kidney Disease in the 21st Century |
| Q33889472 | Diet and Diabetic Kidney Disease: Plant Versus Animal Protein. |
| Q92099930 | Effect of fosinopril on the renal cortex protein expression profile of Otsuka Long-Evans Tokushima Fatty rats |
| Q48347744 | Effect of valsartan on kidney outcomes in people with impaired glucose tolerance |
| Q93025188 | Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study |
| Q64110582 | Efficacy of Co-administration of Liuwei Dihuang Pills and Ginkgo Biloba Tablets on Albuminuria in Type 2 Diabetes: A 24-Month, Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial |
| Q58607875 | Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial |
| Q97531568 | Frequency of alcohol drinking modifies the association between salt intake and albuminuria: a 1-year observational study |
| Q54979361 | Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes - An observational follow-up study. |
| Q90152926 | Guidelines for clinical evaluation of chronic kidney disease : AMED research on regulatory science of pharmaceuticals and medical devices |
| Q28080717 | Improvements in the Management of Diabetic Nephropathy |
| Q50730577 | Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome. |
| Q45096217 | Inhibiting post-translational core fucosylation protects against albumin-induced proximal tubular epithelial cell injury |
| Q47128084 | Is Change in Albuminuria a Surrogate Marker for Cardiovascular and Renal Outcomes in Type 1 Diabetes? |
| Q91046009 | Kidney disease trials for the 21st century: innovations in design and conduct |
| Q53749313 | Low Sodium Diet, Vitamin D, or Both for RAASi-Resistant, Residual, Proteinuria in CKD? The ViRTUE Trial Points the Way Forward but Is Not the Last Word. |
| Q57750140 | Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA |
| Q90470119 | Microalbuminuria and cardiorenal risk: old and new evidence in different populations |
| Q47735079 | Modelling diabetic nephropathy in mice. |
| Q39246562 | Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis |
| Q91654839 | Peri-transplant renal dysfunction in patients with non-alcoholic steatohepatitis undergoing liver transplantation |
| Q88805574 | Proposed Imprecision Quality Goals for Urinary Albumin/Creatinine Ratio |
| Q38984932 | Proteinuria in Dent disease: a review of the literature |
| Q92565845 | Proteinuria-take a closer look! |
| Q91943696 | Randomized Controlled Trial of Exercise in CKD-The RENEXC Study |
| Q48098900 | Rationale and protocol of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy |
| Q37697744 | Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial |
| Q91707078 | Refining the Mouse Subtotal Nephrectomy in Male 129S2/SV Mice for Consistent Modeling of Progressive Kidney Disease With Renal Inflammation and Cardiac Dysfunction |
| Q90259951 | Renal and extrarenal effects of fibroblast growth factor 23 |
| Q40972293 | Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. |
| Q38653194 | Role of albumin and its modifications in glomerular injury |
| Q39631863 | Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus |
| Q39173994 | The Tubulointerstitial Pathophysiology of Progressive Kidney Disease |
| Q55140376 | Variability in response to albuminuria-lowering drugs: true or random? |
Search more.